Article Text
Abstract
Informed consent may be seriously compromised if patients fail to understand the experimental nature of the trial in which they are participating. Using focus groups, the authors explored how prospective trial participants interpret and understand the science of clinical trials by using patient information sheets relative to their medical condition. An opportunity was provided to hear in the patients’ own words how they interpret the information and why there is variable understanding. Respondents struggled to comprehend the meaning and purpose of concepts such as randomisation and double blinding, and found them threatening to their ideas of medical care. Suggestions are made about how to improve the national guidelines on written information for trial participants and pretesting of the information sheets is advocated.
- RCT, randomised controlled trial
- REC, research ethics committee
- comprehension
- controlled clinical trials
- focus groups
- informed consent
- qualitative research
Statistics from Altmetric.com
Footnotes
-
This study was funded by NHS Lanarkshire Research Ethics Committee.
-
Competing interests: none declared
Read the full text or download the PDF:
Other content recommended for you
- Clinical research on COVID-19: perceptions and barriers to participation in The Gambia
- Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?
- Is it ethical to keep interim findings of randomised controlled trials confidential?
- Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception
- Should desperate volunteers be included in randomised controlled trials?
- Randomised placebo-controlled trials of surgery: ethical analysis and guidelines
- Simplified consent in cluster randomised trials: the new EU Clinical Trials Regulation does not provide sufficient guidance
- Understanding, interests and informed consent: a reply to Sreenivasan
- The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals
- Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study